Taihua plc, an investment holding company, develops, manufactures, distributes, and traditional Chinese medicine (TCM) products and active pharmaceutical ingredients (APIs) in the People’s Republic of China. The company operates in four segments: Paclitaxel, Homoharringtonine, TCM Products, and Forsythia. Its APIs products include paclitaxel, which is extracted from yew tree for the treatment of ovaries, breast, lungs, skin, and mucous membranes cancer; and Homoharringtonine, an alkaloid extracted from cephalotaxus tree for the treatment of acute myeloid leukaemia and other cancers. The company also offers TCM products, including gengnianan tablet, duzhong pingya tablet, zaoren anshen keli, bunao anshen tablet, jiangzi jianfei tablet, dabaidu capsule, runing tablet, and bian tong pian. In addition, it cultivates, harvests, and sells Forsythia, a flowering shrub for use as the basis of TCM preparations. The company was formerly known as China Natural Plc and changed its name to Taihua plc in September 2006. Taihua plc was incorporated in 2006 and is based in Xi'an, the People’s Republic of China.
taihua plc (TAIH:London)
No. 16 Zhong Hua
Room 201, Unit 3
239 KeJi Road, Hi-tech Zone
Phone: 86 29 8832 6501
Fax: 86 29 8832 6502www.taihplc.com
|No competitor information is available for TAIH.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact TAIHUA PLC, please visit www.taihplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.